Alopecia, congenital

Summary

Alopecia, congenital (MONDO:0010229) is a disease. A subtype of alopecia, isolated — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	alopecia, congenital
Mondo ID	MONDO:0010229
MeSH	C535981
OMIM	300042
ICD-10-CM	Q84.0
NCIT	C35790
SNOMED CT	2965006
UMLS	C0265992
MedGen	78581
GARD	0001470
Is cancer (heuristic)	no

Also known as: alopecia, congenital · ALPC · congenital alopecia

Disease family

This is a subtype of alopecia, isolated. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › disorder of pilosebaceous unit › hair anomaly › alopecia › alopecia, isolated › alopecia, congenital

Related subtypes (7): alopecia areata 1, familial focal alopecia, alopecia, androgenetic, 1, alopecia universalis congenita, alopecia, androgenetic, 2, alopecia areata 2, alopecia, androgenetic, 3

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.